Ikena Oncology, Inc. IKNA
We take great care to ensure that the data presented and summarized in this overview for Ikena Oncology, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IKNA
View all-
Atlas Venture Life Science Advisors, LLC5.02MShares$8.78 Million0.89% of portfolio
-
Bvf Inc San Francisco, CA4.77MShares$8.35 Million0.2% of portfolio
-
Blue Owl Capital Holdings LP New York, NY3.89MShares$6.81 Million1.46% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.54MShares$6.19 Million0.11% of portfolio
-
Omega Fund Management, LLC Boston, MA2.25MShares$3.94 Million3.31% of portfolio
-
Chi Advisors LLC New York, NY2.18MShares$3.82 Million4.65% of portfolio
-
Black Rock Inc. New York, NY1.83MShares$3.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.53MShares$2.68 Million0.0% of portfolio
-
Verition Fund Management LLC Greenwich, CT1.13MShares$1.99 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny777KShares$1.36 Million0.0% of portfolio
Latest Institutional Activity in IKNA
Top Purchases
Top Sells
About IKNA
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Insider Transactions at IKNA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 04
2023
|
Orbimed Advisors LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
153,121
+6.37%
|
-
|
|
Aug 04
2023
|
David P Bonita |
BUY
Grant, award, or other acquisition
|
Indirect |
153,121
+6.37%
|
-
|
|
Jun 24
2022
|
David P Bonita |
SELL
Open market or private purchase
|
Indirect |
162,000
-3.78%
|
$648,000
$4.87 P/Share
|
|
Jun 24
2022
|
Orbimed Advisors LLC Director |
SELL
Open market or private purchase
|
Indirect |
162,000
-3.78%
|
$648,000
$4.87 P/Share
|
|
Jun 23
2022
|
David P Bonita |
SELL
Open market or private purchase
|
Indirect |
23,419
-1.2%
|
$70,257
$3.71 P/Share
|
|
Jun 23
2022
|
Orbimed Advisors LLC Director |
SELL
Open market or private purchase
|
Indirect |
23,419
-1.2%
|
$70,257
$3.71 P/Share
|
|
Jun 22
2022
|
David P Bonita |
SELL
Open market or private purchase
|
Indirect |
66,806
-3.37%
|
$200,418
$3.55 P/Share
|
|
Jun 22
2022
|
Orbimed Advisors LLC Director |
SELL
Open market or private purchase
|
Indirect |
66,806
-3.37%
|
$200,418
$3.55 P/Share
|
|
Jan 18
2022
|
Maude Tessier Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
71,786
+21.71%
|
$215,358
$3.87 P/Share
|
|
Jan 11
2022
|
Xiaoyan Michelle Zhang Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
964
-2.12%
|
$11,568
$12.0 P/Share
|
|
Jan 11
2022
|
Xiaoyan Michelle Zhang Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
964
+2.08%
|
$1,928
$2.15 P/Share
|
|
Jan 10
2022
|
Xiaoyan Michelle Zhang Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
36
-0.08%
|
$432
$12.0 P/Share
|
|
Jan 10
2022
|
Xiaoyan Michelle Zhang Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36
+0.08%
|
$72
$2.15 P/Share
|
|
Dec 14
2021
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
5,959
-0.48%
|
$83,426
$14.0 P/Share
|
|
Dec 14
2021
|
Jean Francois Formela |
SELL
Open market or private sale
|
Indirect |
5,959
-0.48%
|
$83,426
$14.0 P/Share
|
|
Dec 13
2021
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
8,330
-0.66%
|
$116,620
$14.64 P/Share
|
|
Dec 13
2021
|
Jean Francois Formela |
SELL
Open market or private sale
|
Indirect |
8,330
-0.66%
|
$116,620
$14.64 P/Share
|
|
Dec 10
2021
|
Xiaoyan Michelle Zhang Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,000
-2.2%
|
$14,000
$14.76 P/Share
|
|
Dec 10
2021
|
Xiaoyan Michelle Zhang Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+2.15%
|
$2,000
$2.15 P/Share
|
|
Dec 10
2021
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
11,989
-0.95%
|
$179,835
$15.03 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 306K shares |
|---|